Latest Breaking News On - Caribou biosciences inc - Page 1 : comparemela.com

Caribou Biosciences, Inc (NASDAQ:CRBU) Shares Bought by Avidity Partners Management LP

Avidity Partners Management LP lifted its holdings in shares of Caribou Biosciences, Inc. (NASDAQ:CRBU – Free Report) by 5.1% during the 4th quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The institutional investor owned 6,360,212 shares of the company’s stock after acquiring an additional 310,000 shares during the quarter. […]

United statesCaribou biosciences incAsset management coCitigroup incVanguard group incMitsubishi ufjExchange commissionBarclays plcAvidity partners managementCaribou biosciencesFree reportPartners managementLaurion capital managementGet free reportVisit holdingschannelCaribou biosciences daily

Caribou Biosciences Presents Encouraging Clinical Data from CB-010 ANTLER Phase 1 Trial in Second-line LBCL Patients at the 2024 American Society of Clinical Oncology (ASCO) Annual Meeting

Caribou Biosciences Presents Encouraging Clinical Data from CB-010 ANTLER Phase 1 Trial in Second-line LBCL Patients at the 2024 American Society of Clinical Oncology (ASCO) Annual Meeting
wallstreet-online.de - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from wallstreet-online.de Daily Mail and Mail on Sunday newspapers.

Mccormick placeUnited statesJason obyrneSteve kannerTonia nesheiwatRachel haurwitzMehdi hamadaniPeggy vorwaldTim kellySamy figueroaAmerican society of clinical oncologyCaribou biosciences incCollege of wisconsinHuntsman cancer instituteUniversity of utahExchange commission

Caribou Biosciences : Corporate Presentation May 2024

May 2024 Corporate presentation Transformative genome-edited therapies for patients .

Drug administrationCaribou biosciences incExchange commissionPrivate securities litigation reform actCaribou biosciencesAnnual report

Caribou Biosciences Presents Encouraging Clinical Data from

CB-010 allogeneic CAR-T cell therapy with partial HLA matching has potential to rival efficacy and safety profile of approved autologous CAR-T cell.

Mccormick placeUnited statesSamy figueroaRachel haurwitzSteve kannerTim kellyPeggy vorwaldJason obyrneMehdi hamadaniTonia nesheiwatCaribou biosciences incHuntsman cancer instituteUniversity of utahAmerican society of clinical oncologyExchange commissionCollege of wisconsin

Caribou Biosciences : KOL discussion of CB-010 ANTLER Phase 1 final trial data at ASCO

June 2, 2024 CB-010 ANTLER Phase 1 trial update and KOL discussion Transformative genome-edited.

Drug administrationCaribou biosciences incExchange commissionPrivate securities litigation reform actCaribou biosciencesAnnual report